PPT-“Weighing” in on GLP-1 Receptor Agonists

for People With HIV Suman Srinivasa MD MS Massachusetts General Hospital Harvard Medical School Boston MA Financial Relationships With Ineligible Companies Formerly Described as Commercial Interests by the ACCME Within the Last 2 Years. Pharmacodynamics. Pharmacodynamics. The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects are produced . The study of what drugs do to the body and how they do it . 148 The glucagon-like peptide-1 (GLP-1) receptor agonist class of medications has distinct benets and limitations that provide an opportunity to individualize the treatment of patients with type 2 di Therapies in Type 2 Diabetes. DR.M.Mukhyaprana. . Prabhu. Professor of Internal Medicine. Kasturba. Medical College, . Manipal. ,. Manipal. University, India. 2. nd. International Endocrine Conference. Add on to insulin. EFFICACY AND TOLERABILITY. OF GLP-1 RECEPTOR AGONISTS. AND DPP-4 INHIBITORS AS ADDON THERAPY TO INSULIN . Complementing Insulin Therapy to Achieve Glycemic. Control. Anthony H. Barnett . Introduction/Overview. Lowering HbA1c Reduces the Risk of Microvascular Complications -- But What About Macrovascular Complications?. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM . Oral hypoglycemics. Factors to consider:. Cost. Availability. Side effects. Tolerability. Risk. Accessory benefits. metformin. Metformin is the . preferred initial pharmacologic agent . for the treatment of type 2 diabetes. . Nervous System. Part 2. . Thomas E. Tenner, Jr., Ph.D.. Dept. of Medical Education. Dept. Pharmacology & Neuroscience. tom.tenner@ttuhsc.edu. 743-7169. 1. Recommended Background Reading :.  . Chapters 7, 8, 9, and 10 . Pain. . Pain. persists Pain persists. or increases or increases. 1. . Non. -. opioid. ± adjuvant. 2. Weak . opioid. ± non-. opioid. ± adjuvant. 3. Strong . opioid. Anna Maria Nardiello. 1,. *, Lucia Sessa. 1,2. , Jacopo Santoro. 1. and Stefano Piotto. 1,2. 1. . Department of Pharmacy, University of Salerno, . Fisciano. , 84084, Italy. 2. . Research. Centre for . Graded Dose-response Relationships. Agonist . drugs mimic the action of the original endogenous ligand for the receptor (for example, isoproterenol mimics norepinephrine on β1 . receptors . of the heart). The magnitude of the drug effect depends on the drug concentration at the receptor site, which, in turn, is determined by both the dose of drug administered and by the drug’s pharmacokinetic profile, such as rate of absorption, distribution, metabolism, and elimination. VBC-612. Unit-1. P.G.. 16.10.2020. 28.10.2020. Nuclear receptors . are intracellular proteins expressed in the nucleus of a cell that have a binding site for a particular steroid molecule. . Nuclear receptors . Lispro 5-15 Hrs 1-2 4-5 NPH 1-2 Hrs 5-7 13-18 Lente 1-3 Hrs 4-8 13-20 Ultralente 2-4 Hrs 8-10 18-30 INT. J. DIAB. DEV. COUNTRIES (2000), VOL. 20 oxidation are also reduced by metformin. Metformin Biopsy-Confirmed DIO Mouse Model. JJ Nestor. 1. , K Rigbolt. 2. , M Feigh. 2. , D Parkes. 3. , MS Harris. 1. , 1. Altimmune, Inc., Gaithersburg, MD; 2. Gubra, Horsholm, Denmark; 3. DGP Scientific, Del Mar, CA. Diabetes Management . for the Cardiologist. Confidential. Do Not Distribute. 1. To understand the physiologic relationships between cardiovascular disease (CVD) and Type 2 Diabetes Mellitus (DM), and review the statistics behind the risk.